Tag: Monoclonal antibody

Giant Cell Arteritis (GCA) affects approximately 20 in 100,000 individuals over the age of 50. For patients with GCA, understanding the mechanism of action of tocilizumab is key to appreciating how this targeted therapy helps manage the disease. Tocilizumab works by blocking the pro-inflammatory cytokine interleukin-6 (IL-6), thereby inhibiting the immune system's inflammatory response that damages the blood vessels in GCA.

In July 2024, the U.S. Food and Drug Administration (FDA) approved donanemab, also known as Kisunla, for the treatment of early symptomatic Alzheimer's disease. If you are wondering **what is the Eli Lilly memory drug**, Kisunla represents a significant advancement by targeting the underlying pathology of the disease rather than just managing symptoms.

In clinical trials for donanemab (brand name Kisunla), approximately 37% of participants experienced amyloid-related imaging abnormalities (ARIA), a key safety consideration for this Alzheimer's treatment. Understanding **what are the side effects of the drug donanemab?** is crucial for patients, caregivers, and clinicians considering this therapy.

Ocrevus (ocrelizumab) was the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for both relapsing and primary progressive forms of multiple sclerosis in adults. But what drug category is Ocrevus? It belongs to a class of highly specific, targeted immunotherapies known as anti-CD20 monoclonal antibodies, which selectively deplete certain immune cells believed to drive MS pathology.

With a terminal elimination half-life of approximately 26 to 28 days, understanding what is the elimination of ocrelizumab is crucial for comprehending its sustained effects on B-cell depletion. Unlike many small-molecule drugs, this large monoclonal antibody is cleared primarily through catabolism rather than classic hepatic or renal metabolism, a process it shares with the body's own antibodies.

The mean elimination half-life of natalizumab is approximately 11 days [1.2.1, 1.2.4]. This key pharmacokinetic parameter is crucial for understanding its dosing schedule and therapeutic effect in treating multiple sclerosis and Crohn's disease. So, what is the half life of natalizumab elimination and what factors influence it?

Originally approved for non-Hodgkin's lymphoma, rituximab is increasingly used for autoimmune diseases, but is rituximab considered an immunosuppressant? The answer lies in its targeted B-cell depletion mechanism, which directly impacts a core component of the immune system.

According to the U.S. Drug Enforcement Administration (DEA), controlled substances are categorized based on their potential for abuse and accepted medical use. However, Tepezza, also known by its generic name teprotumumab-trbw, is a prescription-only biologic medication that is **not a controlled substance**. Its specific pharmacological profile and lack of potential for abuse mean it does not fall under the strict federal regulations of the Controlled Substances Act.

More than 21 antibody therapeutics were granted a first approval in at least one country during 2024 [1.2.3]. So, **what is the new monoclonal antibody drug?** These lab-made proteins are revolutionizing treatment for cancer, autoimmune disorders, and infectious diseases by targeting specific cells [1.8.1, 1.8.4].

Clinical trials for multiple sclerosis (MS) showed that TYSABRI reduced the number of relapses by 67% compared to placebo over two years. The question is, what are the benefits of TYSABRI and how does this powerful monoclonal antibody help patients with MS and Crohn's disease?